Orion Corp New B Shs (ORINF) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Orion Oyj Class A.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.461 Good afternoon and welcome to Orion's earnings conference call and webcast for the financial 00:00:05.461 -- 00:00:09.224 period of January-September 2025. 00:00:09.909 -- 00:00:15.559 My name is Tuukka Hirmonen. I'm the head of investor relations here at Orion. 00:00:15.559 -- 00:00:20.448 In a few moments, we will start with the presentation by our CEO and president, Mrs. 00:00:20.448 -- 00:00:25.835 Liisa Hurme. After which then we will have Q&A session where you can pose questions 00:00:25.835 -- 00:00:31.103 both to Liisa and also to our CFO René Lindell. 00:00:31.103 -- 00:00:35.670 We will be first taking questions from the conference call lines and after that we will 00:00:35.670 -- 00:00:38.114 turn to the webcast 00:00:38.114 -- 00:00:43.502 questions so you can type in your questions using the chat box in the webcast 00:00:43.502 -- 00:00:46.363 view in the bottom. 00:00:47.382 -- 00:00:52.427 And just before I let Liisa to take the stage, I'd like to draw your attention to 00:00:52.427 -- 00:00:56.669 this disclaimer regarding forward-looking statements. 00:00:56.731 -- 00:01:00.034 But with that, it's my pleasure to hand over to Liisa. 00:01:00.034 -- 00:01:00.874 Liisa. 00:01:00.874 -- 00:01:02.796 Thank you, Tuukka. 00:01:02.796 -- 00:01:09.761 And welcome to Orion Q3 webcast on my behalf as well. 00:01:09.803 -- 00:01:14.285 Here are some highlights from Q3 2025. 00:01:16.525 -- 00:01:21.631 Nubeca received approval from the European Commission for 00:01:21.631 -- 00:01:23.614 use of darolutamide 00:01:23.614 -- 00:01:29.261 and ADT, androgen deprivation therapy, in patients with metastatic 00:01:29.261 -- 00:01:33.143 hormone sensitive prostate cancer. 00:01:34.407 -- 00:01:39.233 Nubeca also reached all-time high ...